{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:22:51Z","timestamp":1784647371098,"version":"3.55.0"},"reference-count":16,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Grants for Health Research Project 2018 of Spain ("],"award-info":[{"award-number":["Grants for Health Research Project 2018 of Spain ("]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006541","name":"Consejer\u00eda de Sanidad, Comunidad de Madrid","doi-asserted-by":"publisher","award":["Sponsor of the Clinical Trial: La Paz University H"],"award-info":[{"award-number":["Sponsor of the Clinical Trial: La Paz University H"]}],"id":[{"id":"10.13039\/501100006541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Invasive aspergillosis is the most important cause of morbidity and mortality in patients with haematological diseases. At present, voriconazole is the first-line treatment for invasive fungal disease. The pharmacokinetic interindividual variability of voriconazole depends on genetic factors. CYP450 is involved in 70%\u201375% of total metabolism of voriconazole, mainly CYP3A4 and CYP2C19, with the remaining 25%\u201330% of metabolism conducted by monooxygenase flavins. CYP2C19 single nucleotide polymorphisms could explain 50%\u201355% of variability in voriconazole metabolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The main objective is to compare efficiency of pre-emptive voriconazole genotyping with routine practice. The primary outcome is serum voriconazole on the fifth day within the therapeutic range. The secondary outcome is the combined variables of therapeutic failure and adverse events within 90\u2009days of first administration, associated with voriconazole. A total of 146 patients at risk of invasive aspergillosis who will potentially receive voriconazole will be recruited, and CYP2C19 will be genotyped. If the patient ultimately receives voriconazole, they will be randomised (1:1 experimental\/control). In the experimental arm, patients will receive a dose according to a pharmacogenetic algorithm, including CYP2C19 genotype and clinical and demographic information. In the control arm, patients will receive a dose according to clinical practice guidelines. In addition, a Spanish National Healthcare System (NHS) point-of-view cost-effectiveness evaluation will be performed. Direct cost calculations for each arm will be performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This trial will provide information about the viability and cost-effectiveness of the implementation of a pre-emptive voriconazole genotyping strategy in the Spanish NHS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>A Spanish version of this protocol has been evaluated and approved by the La Paz University Hospital Ethics Committee and the Spanish Agency of Medicines and Medical Devices. Trial results will be submitted for publication in an open peer-reviewed medical speciality-specific publication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>Eudra-CT: 2019-000376-41 and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT04238884\">NCT04238884<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-037443","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:40:33Z","timestamp":1680716433000},"page":"e037443","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04238884","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"given":"Jaime","family":"Monserrat Villatoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Est\u00e9banez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez de la Gu\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ram\u00edrez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Fr\u00edas Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-3263","authenticated-orcid":false,"given":"Alberto M","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"2023040221342074000_10.10.e037443.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.10.019"},{"key":"2023040221342074000_10.10.e037443.2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/jac\/dkx527","article-title":"Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study","volume":"73","author":"Lestrade","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023040221342074000_10.10.e037443.3","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2023040221342074000_10.10.e037443.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2011.01.010"},{"key":"2023040221342074000_10.10.e037443.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw444"},{"key":"2023040221342074000_10.10.e037443.6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"2023040221342074000_10.10.e037443.7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2023040221342074000_10.10.e037443.8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2023040221342074000_10.10.e037443.9","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.53"},{"key":"2023040221342074000_10.10.e037443.10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2019.06.026","article-title":"Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: an exploratory study in a Spanish population","volume":"54","author":"Dap\u00eda","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023040221342074000_10.10.e037443.11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.371"},{"key":"2023040221342074000_10.10.e037443.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.10.021"},{"key":"2023040221342074000_10.10.e037443.13","first-page":"467","article-title":"Pharmacogenomics and individualized medicine: translating science into practice","volume":"92","author":"Crews","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2023040221342074000_10.10.e037443.14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cts.12526","article-title":"Clinical implementation of pharmacogenetic testing in a hospital of the Spanish National health system: strategy and experience over 3 years","volume":"11","author":"Borobia","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2023040221342074000_10.10.e037443.15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.137"},{"key":"2023040221342074000_10.10.e037443.16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/pgs-2020-0029","article-title":"Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice","volume":"21","author":"Garc\u00eda","year":"2020","journal-title":"Pharmacogenomics"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-037443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:40:41Z","timestamp":1680716441000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-037443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,1]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/bmjopen-2020-037443"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-037443","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}